EULAR News: IL-12/23 and IL-23 Blockers May Prevent Progression to PsA in PsO Patients
New research suggests that interleukin (IL)-12/23 and IL-23 inhibitors reduce the incidence of progression to psoriatic arthritis (PsA) among people with psoriasis when compared to tumor necrosis factor inhibitors (TNFi) and IL-17 inhibitors. The findings, which were presented at EULAR 2024 in Vienna, Austria, held in naïve and bio-experienced patients. For the new retrospective study, […]